Molbio Diagnostics Q1 FY27 Performance Update
Molbio Diagnostics Ltd · Investor Presentation · 08 Sept 2026, 8:27 pm
Molbio Diagnostics Q1 FY27 Performance Update Molbio Diagnostics reported Q1 FY27 total income of ₹411.5 Cr, up from ₹100.5 Cr in Q1 FY26, boosted by ~₹57 Cr of deferred Q4 FY26 export orders. EBITDA turned around to ₹103.7 Cr (25.2% margin) versus a loss of ₹14.5 Cr in Q1 FY26, while PAT reached ₹52.7 Cr against a net loss of ₹23.9 Cr. Growth was driven by Truenat test kit volumes reaching 6.2 Mn units. Capacity utilization stood at 58.25% for test kits and 42.30% for devices in FY26.
Original exchange filing (PDF)
More announcements from Molbio Diagnostics Ltd
- Transcript of Earnings Call with analysts and investors for the quarter and half year ended on September 30, 2026 · 11 Nov 2026
- Monitoring Agency Report on the utilization of proceeds raised through issuance of equity shares by way of Public Issue of the Company · 07 Nov 2026
- Audio Recording of Earnings call held on November 05,2026 for the quarter and half year ended September 30,2026. · 06 Nov 2026
- Outcome of Board meeting held on Thursday, November 05, 2026 · 06 Nov 2026
- Investor presentation · 05 Nov 2026
- Outcome of the Board Meeting · 05 Nov 2026
- Molbio Diagnostics Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 05 Nov 2026
- Intimation of Earnings Conference Call on November 05, 2026, at 05:30 P.M. IST to discuss the financial performance of the Company for the quarter and half year ended September 30, 2026. · 05 Nov 2026
